UBS Group AG - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 146 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$3,983,029
-17.1%
340,721
-4.7%
0.00%
-50.0%
Q2 2023$4,805,136
-25.2%
357,525
-7.8%
0.00%0.0%
Q1 2023$6,427,569
-41.5%
387,670
-34.3%
0.00%
-50.0%
Q4 2022$10,979,246
+160.1%
590,282
+79.4%
0.00%
+100.0%
Q3 2022$4,221,000
+85.2%
329,043
+1.2%
0.00%
+100.0%
Q2 2022$2,279,000
-12.6%
325,012
+3.3%
0.00%0.0%
Q1 2022$2,607,000
+33.0%
314,515
+8.6%
0.00%0.0%
Q4 2021$1,960,000
-16.5%
289,667
-34.6%
0.00%0.0%
Q3 2021$2,347,000
+2.9%
442,914
+11.7%
0.00%0.0%
Q2 2021$2,281,000
-11.5%
396,661
-29.0%
0.00%0.0%
Q1 2021$2,577,000
+134.1%
558,992
+69.6%
0.00%
Q4 2020$1,101,000
+34.4%
329,591
+19.5%
0.00%
Q3 2020$819,000
+9000.0%
275,850
+12025.3%
0.00%
Q1 2020$9,000
-86.8%
2,275
-87.5%
0.00%
Q4 2019$68,000
-94.3%
18,175
-92.0%
0.00%
Q3 2019$1,202,000
+1314.1%
226,480
+917.4%
0.00%
Q2 2019$85,000
+23.2%
22,260
-37.8%
0.00%
Q4 2018$69,000
-21.6%
35,811
+53.9%
0.00%
Q3 2018$88,000
+131.6%
23,271
+90.8%
0.00%
Q2 2018$38,000
-9.5%
12,198
+14.0%
0.00%
Q4 2017$42,000
+600.0%
10,703
+345.2%
0.00%
Q3 2017$6,000
-64.7%
2,404
-60.2%
0.00%
Q2 2017$17,000
-55.3%
6,045
-88.7%
0.00%
Q2 2016$38,000
+192.3%
53,536
+1581.9%
0.00%
Q2 2015$13,000
+550.0%
3,183
+536.6%
0.00%
Q1 2015$2,000
+100.0%
500
+66.7%
0.00%
Q4 2014$1,0003000.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q3 2020
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 148,281$2,4587.14%
GABLES CAPITAL MANAGEMENT INC. 409,080$6,782,5464.74%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 10,355,099$171,687,5413.83%
JW Asset Management, LLC 563,392$9,341,0393.58%
Quantedge Capital Pte Ltd 324,700$5,383,5262.10%
Paradiem, LLC 236,628$3,923,2921.22%
SummerHaven Investment Management, LLC 100,592$1,667,8150.97%
Capital Impact Advisors, LLC 46,096$764,2720.94%
Yorktown Management & Research Co Inc 50,000$829,0000.89%
Seaport Global Advisors, LLC 15,598$258,6150.82%
View complete list of CATALYST PHARMACEUTICALS INC shareholders